Drug Developer 89Bio Soars as NASH Drug Succeeds in Midstage Study Drug Developer 89Bio Soars as NASH Drug Succeeds in Midstage Study
Drug developer 89Bio said on Wednesday its experimental treatment for liver disease NASH met the main goals of a small mid-stage study.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Gastroenterology News Source Type: news
More News: Gastroenterology | Liver | Liver Disease | Liver Transplant | Study | Transplant Surgery | Transplants | Urology & Nephrology